[ad_1]
meIn the dispute over vaccine deliveries, the EU Commission demands to know the data of the pharmaceutical company Astra-Zeneca. “The EU requires information from the company no later than January 29, why it wants to deliver fewer doses of vaccines to the EU,” EU Commission circles said Monday night after another meeting of representatives of the company with members from EU countries. The contract foresees a pre-production of cans worth millions not only for the current quarter, but also for the fourth quarter of 2020. Furthermore, the contract with the British-Swedish company from the EU guarantees access to the company’s production. data. “So the commission now wants to use data to see what happened in which plant and when,” he said in commission circles.
The EU now also wants to introduce an export transparency mechanism to see where the vaccine produced in the EU is distributed. The EU is asking Astra-Zeneca to significantly improve the delivery offer for the first quarter. The delivery issues were significantly different from those of Biontech-Pfizer. The week-long delivery disruption there could be explained “conclusively” with the preparation for the expansion of production. This is not the case for the Astra-Zeneca group.
The EU Health Commissioner highlighted on Twitter that after the talks there was not enough clarity and explanations from the company. Astra-Zeneca was asked to submit detailed delivery plans to the EU. Another meeting with company representatives is scheduled for Wednesday.
Apparently, the legal process against the pharmaceutical company has not yet started. For the EU Commission and member states, the priority now is to ensure the prompt delivery of as many doses of vaccine as possible, should Astra-Zeneca receive marketing approval, the commission said. According to the Federal Ministry of Health, this should be the case on Friday.
Meanwhile, the media reported that the Astra-Zeneca vaccine had comparatively low efficacy in older people and could not be approved for the 65+ age group. As the newspaper “Bild” reports, referring to government circles, the effectiveness of the Astra Zeneca vaccine is less than ten percent, while the “Handelsblatt” reports, referring to coalition circles, an effectiveness of eight percent. . Astra-Zeneca rejected reports of up to eight percent reduced effectiveness in older people. The information was “completely incorrect,” the company said.
